Leinco Technologies

Anti-Human IL-27 (NT)

Product Code:
 
LEI-I-501
Product Group:
 
Primary Antibodies
Host Type:
 
Rabbit
Antibody Clonality:
 
Polyclonal
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Immunohistochemistry- Paraffin Embedded (IHC-P)
  • Western Blot (WB)
Shipping:
 
Ambient
Storage:
 
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-I-501-20ug20 ug£221.00
Quantity:
LEI-I-501-0.1mg0.1 mg£591.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:I-513
Long Description:
Interleukin-27 (IL-27) is a novel IL-12 family member that plays a role in the early regulation of T helper cell 1 initiation, including induction of T-bet and IL-12 receptor beta 2 expression.1 IL-27 is produced by antigen-presenting cells2 and plays an important function in regulating the activity of B and T lymphocytes.3 IL27 may be a potential therapeutic agent against rheumatoid arthritis (RA) at the onset of the disease.4
Target:
IL-27

References

1. Yoshimoto T et al. (2004) Cancer Res. 64: 1152 2. De Sauvage FJ et al. (2003) Proceedings of the National Acad of Sci of USA 100: 15047 3. Devergne O et al. (2006) J Immunol. 176: 5890 4. Liew FY et al. (2008) Ann Rheum Dis. 67: 1474